Literature DB >> 17000697

Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck.

Zhengdong Zhang1, Li-E Wang, Erich M Sturgis, Adel K El-Naggar, Waun K Hong, Christopher I Amos, Margaret R Spitz, Qingyi Wei.   

Abstract

PURPOSE: Alteration of the FAS/FAS ligand (FASLG) pathway regulating cell death may lead to cancer development, but the effects of functional promoter polymorphisms of the FAS and FASLG genes on risk of squamous cell carcinoma of the head and neck (SCCHN) are unknown.
DESIGN: We genotyped the FAS -1377 G>A, FAS -670 A>G, FASLG -844 C>T, and FASLG IVS2nt -124 A>G polymorphisms in 721 case patients with SCCHN and 1,234 cancer-free non-Hispanic White control subjects frequency-matched by age and sex. Multivariate logistic regression was used to assess the adjusted odds ratios (OR) and 95% confidence intervals (CI).
RESULTS: Compared with the FAS -1377 GG and -670 AA genotypes, the FAS -1377 AA and -670 (GG+AG) genotypes were associated with an increased risk of SCCHN (OR, 2.23; 95% CI, 1.07-4.64 and OR, 1.24; 95% CI, 1.01-1.52, respectively), whereas no risk of SCCHN was associated with any of the FASLG genotypes. When we used the combined FAS -1377 (GG+AG)/-670 AA genotypes as the reference, we found that the individuals carrying the FAS -1377 AA/-670 (GG+AG) had the highest risk (OR, 2.69; 95% CI, 1.24-5.83), whereas individuals carrying genotypes other than FAS -1377 (GG+AG)/-670 AA had a higher risk of SCCHN (OR, 1.24; 95% CI, 1.01-1.52). Furthermore, the elevated risk was particularly evident for pharyngeal cancer with the larger tumors without regional lymph metastasis (OR, 1.77; 95% CI, 1.07-2.94).
CONCLUSIONS: The FAS (but not FASLG) polymorphisms seem to contribute to risk of developing SCCHN, particularly the pharyngeal cancer in non-Hispanic Whites. However, potential selection bias warrants future population-based studies to verify the findings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17000697     DOI: 10.1158/1078-0432.CCR-05-1739

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

1.  FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck.

Authors:  Dapeng Lei; Erich M Sturgis; Li-E Wang; Zhensheng Liu; Mark E Zafereo; Qingyi Wei; Guojun Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

2.  The role of FAS, FAS-L, BAX, and BCL-2 gene polymorphisms in determining susceptibility to unexplained recurrent pregnancy loss.

Authors:  Rafael Tomoya Michita; Francis Maria Báo Zambra; Lucas Rosa Fraga; Maria Teresa Sanseverino; Lavínia Schuler-Faccini; José Artur Bogo Chies; Priscila Vianna
Journal:  J Assist Reprod Genet       Date:  2019-04-02       Impact factor: 3.412

3.  FAS -1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls.

Authors:  Li-Xin Qiu; Jian Shi; Hui Yuan; Xin Jiang; Kai Xue; Hai-Feng Pan; Jin Li; Ming-Hua Zheng
Journal:  Hum Genet       Date:  2009-02-19       Impact factor: 4.132

4.  Apoptotic variants as predictors of risk of oropharyngeal cancer recurrence after definitive radiotherapy.

Authors:  Fenghua Zhang; Erich M Sturgis; Yan Sun; Yang Zhang; Qingyi Wei; Caiyun Zhang; Hongliang Zheng; Guojun Li
Journal:  Int J Cancer       Date:  2015-07-27       Impact factor: 7.396

5.  Significant association among the Fas -670 A/G (rs1800682) polymorphism and esophageal cancer, hepatocellular carcinoma, and prostate cancer susceptibility: a meta-analysis.

Authors:  Tao Liu; Li Zuo; Lin Li; Lei Yin; Kai Liang; Hongyuan Yu; Hui Ren; Wen Zhou; Hongwei Jing; Yang Liu; Chuize Kong
Journal:  Tumour Biol       Date:  2014-08-02

6.  Susceptibility to oral cancers with CD95 and CD95L promoter SNPs may vary with the site and gender.

Authors:  Sarika Daripally; Sateesh Reddy Nallapalle; Saritha Katta; Vidudala V T S Prasad
Journal:  Tumour Biol       Date:  2015-05-06

7.  Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.

Authors:  Gudrun Knechtel; Günter Hofmann; Armin Gerger; Wilfried Renner; Tanja Langsenlehner; Joanna Szkandera; Gerald Wolf; Hellmut Samonigg; Peter Krippl; Uwe Langsenlehner
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-05       Impact factor: 4.553

8.  Genetic polymorphisms in the PTPN13 gene and risk of squamous cell carcinoma of head and neck.

Authors:  Jiangong Niu; Yu-Jing Huang; Li-E Wang; Erich M Sturgis; Qingyi Wei
Journal:  Carcinogenesis       Date:  2009-12       Impact factor: 4.944

9.  Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.

Authors:  Prajitha Mohandas Edathara; Manjula Gorre; Sailaja Kagita; Sugunakar Vuree; Anuradha Cingeetham; Santhoshi Rani Nanchari; Phanni Bhushann Meka; Sandhya Annamaneni; Raghunadha Rao Digumarthi; Vishnupriya Satti
Journal:  Tumour Biol       Date:  2015-11-13

10.  Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer.

Authors:  Monica Ter-Minassian; Rihong Zhai; Kofi Asomaning; Li Su; Wei Zhou; Geoffrey Liu; Rebecca Suk Heist; Thomas J Lynch; John C Wain; Xihong Lin; Immaculata De Vivo; David C Christiani
Journal:  Carcinogenesis       Date:  2008-08-29       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.